Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
Giuseppe Buono(Federico II University Hospital), Grazia Arpino(University of Naples Federico II), Antonello Accurso(University of Naples Federico II), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alfonso Amore(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Ernesta Cavalcanti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimiliano D’Aiuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Matilde Pensabene(University of Naples Federico II), Sabino De Placido, Rossella Lauria, Maurizio Montella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Raffaele Tortoriello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Livia Silvia Augustin(St. Michael's Hospital), Francesco Schettini(Target (United States))
Cited by 25
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724